Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $7.8 million.

  • Protagonist Therapeutics' Gains from Investment Securities was N/A to -$5,000 in Q1 2025 from the same period last year, while for Dec 2023 it was $7.9 million, marking a year-over-year change of. This contributed to the annual value of $7.8 million for FY2024, which is 1.32% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Gains from Investment Securities stood at $7.8 million for FY2024, which was down 1.32% from $7.9 million recorded in FY2023.
  • Protagonist Therapeutics' Gains from Investment Securities' 5-year high stood at $7.9 million during FY2023, with a 5-year trough of $3.0 million in FY2020.
  • In the last 3 years, Protagonist Therapeutics' Gains from Investment Securities had a median value of $7.8 million in 2024 and averaged $7.0 million.
  • In the last 5 years, Protagonist Therapeutics' Gains from Investment Securities skyrocketed by 96.35% in 2021 and then declined by 8.33% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Gains from Investment Securities (Yearly) stood at $3.0 million in 2020, then surged by 96.35% to $5.9 million in 2021, then dropped by 8.33% to $5.4 million in 2022, then skyrocketed by 46.70% to $7.9 million in 2023, then fell by 1.32% to $7.8 million in 2024.